Dataset Information


The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.

ABSTRACT: Background and objective:Promoter status of O6-methylguanine-DNA methyltransferase (MGMT) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between MGMT promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. Methods:A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between MGMT promoter methylation and prognosis of GBM patients. Results:Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of MGMT receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR)?=?0.46, 95% confidence interval (CI): 0.41-0.52, p?


PROVIDER: S-EPMC5873285 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3782499 | BioStudies
2020-01-01 | S-EPMC7596890 | BioStudies
| S-EPMC7504655 | BioStudies
2018-01-01 | S-EPMC6277207 | BioStudies
2019-01-01 | S-EPMC6795970 | BioStudies
1000-01-01 | S-EPMC6342854 | BioStudies
2019-01-01 | S-EPMC6886804 | BioStudies
2014-01-01 | S-EPMC3890309 | BioStudies
2018-01-01 | S-EPMC6216462 | BioStudies
2017-01-01 | S-EPMC5524564 | BioStudies